Nano Science and Technology Institute - NSTI  
Nano Science and Technology Institute   Home | Subscribe | Site Map  
  ABOUT | COURSES | EVENTS | PUBLICATIONS | LEADERSHIP | OUTREACH | NEWS | PRESS | JOBS | Nanotechnology Solutions
px
px fade_top
Publications
Nanotech 2008 CDROM
Nanotech 2007 CDROM
Nanotech 2006 CDROM
Nanotech 2005 CDROM
Nanotech 2004 CDROM
3 CDROM Special Offer
Nanotech 2008 Vol. 1
Nanotech 2008 Vol. 2
Nanotech 2008 Vol. 3
Nanotech 2007 Vol. 1
Nanotech 2007 Vol. 2
Nanotech 2007 Vol. 3
Nanotech 2007 Vol. 4
Nanotech 2006 Vol. 1
Nanotech 2006 Vol. 2
Nanotech 2006 Vol. 3
Nanotech 2005 Vol. 1
Nanotech 2005 Vol. 2
Nanotech 2005 Vol. 3
WCM 2005
Nanotech 2004 Vol. 1
Nanotech 2004 Vol. 2
Nanotech 2004 Vol. 3
Nanotech 2003 Vol. 1
Nanotech 2003 Vol. 2
Nanotech 2003 Vol. 3
Nanotech 2002 Vol. 1
Nanotech 2002 Vol. 2
Nanotech 2001 Vol. 1
Nanotech 2001 Vol. 2
MSM 2000
MSM 99
MSM 98
Index of Authors
Index of Keywords
Index of Affiliations
Library Request Form
Shopping Cart
Order Form
 
Publications Publications
Nanotech 2006 Vol. 2
p
 
Technical Proceedings of the 2006 NSTI Nanotechnology Conference and Trade Show, Volume 2
Nanotech 2006 Vol. 2
Technical Proceedings of the 2006 NSTI Nanotechnology Conference and Trade Show, Volume 2
 
Chapter 5: Drug Delivery
 

Development of a Novel Triblock Copolymer Therapeutic Nanoreactor

Authors:A. Ranquin, C. De Vocht, W. Meier, J. Steyaert and P. Van Gelder
Affilation:VUB, BE
Pages:358 - 361
Keywords:tribloc copolymers, nanoreactors, enzyme-prodrug therapy
Abstract:Currently chemotherapy is one of the major strategies to treat cancer patients. It is however limited by several drawbacks such as low bioavailability of chemotoxins, low drug concentrations at the tumor site, systemic toxicity, lack of specificity and drug-resistant tumors. Many different strategies have been proposed to overcome these problems including targeted enzyme-prodrug therapies. However classic enzyme-prodrug therapies suffer from several problems such as immunogenicity of the exogenous enzymes used, non efficient targeting and activation of the prodrugs by endogenous enzymes.
We propose a novel enzyme-prodrug strategy based on the use of therapeutic nanoreactors. In this strategy nanometersized triblock copolymeric (PMOXA-PDMS-PMOXA) vesicles are used to encapsulate the prodrug activating enzyme nucleoside hydrolase of T.vivax. To ensure diffusion of prodrugs and drugs to and from the reactor interior, the nanoreactors are permeabilised by incorporating bacterial outer membrane proteins (OmpF and Tsx) in the reactor wall. We Produced such 200 nm sized nanoreactors and demonstrated the efficient activation of the prodrug 2-fluoroadenosine. We believe that these nanoreactors are promising candidates for in vivo prodrug activation. Targeting of nanoreactors to tumor tissue is possible by the enhanced permeability and retention effect (EPR) and covalent coupling of tumor specific single chain antibodies.
ISBN:0-9767985-7-3
Pages:893
Hardcopy:$185.00
 
Order:Mail/Fax Form
Special:3 CD Set — 15% off with Free Shipping
Up
nanoPRwire™
nanoPRwire
News Headlines
nano World news
 
 
 
 
px
© Nano Science and Technology Institute     About NSTI | Terms of Use | Privacy Policy | Contact